American Society of Hematology, Blood Advances, 23(4), p. 5936-5941, 2020
DOI: 10.1182/bloodadvances.2020002543
Full text: Download
Key Points Patients with acute leukemia present with a prolonged and severe course of COVID-19, which is paralleled by high rates of viremia. Low-intensive chemotherapy seems to be more feasible in patients with acute myeloid leukemia and concomitant SARS-CoV-2 infection.